EGFR and Hyponatremia: For an experimental examination, 5 out of the 6 targeted therapies studied in the RR analysis of high-grade hyponatraemia [19,22–28] were grouped into 2 categories: (1) inhibitors of angiogenesis (brivanib, pazopanib, sorafenib); (2) anti-Epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) or monoclonal antibodies (mAbs) (gefitinib, cetuximab).